DBV Technologies Stock Plummets, Breaking Its €2.60 Support Following a Fundraising Project
The French biotech company falls mid-morning, moving against a slightly bullish Paris market. The stock is trailing at the bottom of the broad index, just days after filing a prospectus to raise up to $150 million on the US market.
The Stock Dives Below Its Moving Averages and Breaks the €2.60 Threshold
DBV Technologies stock is down 3.62% at €2.506 during the session, ranking among the largest declines in the SBF 120, just behind the bottom-ranked Soitec. The stock has broken its support at €2.60, which was the last closing price, and is moving further away from its moving averages: the price is below the MM20 (€2.83) by 11.45%, below the MM50 (€3.00) by 16.47%, and below the MM200 (€3.16) by more than 20%. The RSI at 35 indicates accumulated selling pressure, although it is not yet in a clear oversold zone. Over one month, the decline reaches 11.5%, and nearly 31% over three months, while the annual performance remains positive at 46.7%, a legacy of the late 2025 rally.
The technical context has deteriorated since the break of the €2.75 support, already commented on during the sessions of July 15. According to the statements reviewed, three funds cumulatively hold 3.21% of the capital sold short, a high level even though it has decreased by 0.75 points over thirty days (from 3.96% a month earlier). This decrease signals the beginning of covering short positions, without yet indicating a shift in sentiment; this point deserves to be followed without overinterpretation.
A $150M ATM Program to Fund FDA Filing Scheduled for the Third Quarter
The biotech filed a prospectus with the SEC on July 17 regarding an At-The-Market program that could reach $150 million, through the issuance of American Depositary Shares on the Nasdaq. This mechanism allows it to mobilize capital as needed on the US market, with the flexibility to calibrate issuances based on liquidity windows. The prospect of gradual dilution naturally weighs on the valuation, at a time when the company is preparing to file its regulatory dossier for Viaskin Peanut with the FDA, scheduled for the third quarter of 2026 as announced at the end of June.
It is worth noting that DBV Technologies is listed on Euronext Paris (ordinary shares) and on the Nasdaq (ADS, with a ratio of one ADS for every five ordinary shares since November 2024), with Paris remaining the most liquid market. The next key event to watch is the actual BLA submission in the third quarter, a regulatory milestone crucial for the commercial trajectory of the anti-peanut patch for children aged 4 to 7 years.
